Abstract
Aims To evaluate the associations of dietary indices and quantitative CRF measures in a large, community-based sample harnessing metabolomic profiling to interrogate shared biology.
Methods Framingham Heart Study (FHS) participants underwent maximum effort cardiopulmonary exercise tests for CRF quantification (via peak VO2) and completed semi-quantitative FFQs. Dietary quality was assessed by the Alternative Healthy Eating Index (AHEI) and Mediterranean-style Diet Score (MDS), and fasting blood concentrations of 201 metabolites were quantified.
Results In 2380 FHS participants (54±9 years, 54% female, BMI 28±5 kg/m2), 1-SD higher AHEI and MDS were associated with 5.1% (1.2 ml/kg/min, p<0.0001) and 4.4% (1.0 ml/kg/min, p<0.0001) greater peak VO2 in linear models adjusted for age, sex, total energy intake, cardiovascular risk factors, and physical activity. In participants with metabolite profiling (N=1154), 24 metabolites were concordantly associated with both dietary indices and peak VO2 in multivariable-adjusted linear models (FDR<5%). These metabolites included C6 and C7 carnitines, C16:0 ceramide, and dimethylguanidino valeric acid, which were higher with lower CRF and poorer dietary quality and are known markers of insulin resistance and cardiovascular risk. Conversely, C38:7 phosphatidylcholine plasmalogen and C38:7 and C40:7 phosphatidylethanolamine plasmalogens were associated with higher CRF and favorable dietary quality and may link to lower cardiometabolic risk.
Conclusion Higher diet quality is associated with greater CRF cross-sectionally in a middle-aged community-dwelling sample, and metabolites highlight potential shared favorable effects on health.
Competing Interest Statement
V.L.M. owns stock in Amgen, General Electric, and Cardinal Health. He has received speaking honoraria from, serves as a scientific advisor for, and owns stock options in Ionetix. He has received research funding and speaking honoraria from Siemens Medical Imaging. He has served as a scientific advisor for Curium and has received expert witness fees from Jubilant Draximage. He has received a speaking honorarium from 2Quart Medical. He has received non-financial research support from INVIA Medical Imaging Solutions. In the past 12 months, R.V.S. has served as a consultant for Myokardia, Best Doctors, Amgen, and Cytokinetics. R.V.S. is a co-inventor on a patent for ex-RNAs signatures of cardiac remodeling. The spouse of R.V.S. works for UpToDate (Wolters Kluwer). G.D.L. has research funding from Amgen, Cytokinetics, Applied Therapeutics, AstraZeneca, and Sonivie in relation to projects and clinical trials investigating exercise capacity that are distinct from this work. He has served as a scientific advisor for Pfizer, Merck, Boehringer-Ingelheim, Novartis, American Regent, Relypsa, Cyclerion, Cytokinetics, and Amgen and receives royalties from UpToDate for scientific content authorship related to exercise physiology. M.N. has received speaking honoraria from Cytokinetics.
Funding Statement
The Framingham Heart Study is supported by the National Heart, Lung, and Blood Institute at the National Institutes of Health (contracts N01-HC-25195, HHSN268201500001I, and 75N92019D00031). M.Y.M. is supported by the National Institutes of Health (grant number T32-HL007208). M.E.W. is supported in part by the American Heart Association (grant number 20CDA35310237), the Doris Duke Charitable Foundation (grant number 2021261), and the National Center for Advancing Translational Sciences at the National Institutes of Health through BU-CTSI (grant number 1UL1TR001430). R.S.V. was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine. R.V.S. is supported by the National Institutes of Health (grant number R01-HL136685). G.D.L. is supported by National Institutes of Health (grant number R01-HL131029) and American Heart Association (grant number 15GPSGC24800006). M.N. is supported by National Institutes of Health (grant number K23-HL138260, R01-HL156975) and by a Career Investment Award from the Department of Medicine, Boston University School of Medicine.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Boards at Boston University Medical Campus and Massachusetts General Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimer: The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.
Data Availability
All data produced in the present study are available upon reasonable request to the Framingham Heart Study and the NIH's Database of Phenotypes and Genotypes.
